Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Therapy Trial Clinical Hold Will Be Topic Of FDA, NIH Meetings

Executive Summary

FDA's Biological Response Modifiers Advisory Committee and NIH's Recombinant DNA Advisory Committee will each discuss the latest adverse event to occur in a French gene transfer trial at upcoming meetings
Advertisement

Related Content

Stem Cell Retroviral Gene Therapy Trials May Proceed On Case-By-Case Basis
Stem Cell Retroviral Gene Therapy Trials May Proceed On Case-By-Case Basis
SCID Event Should Be Included In All Retroviral Therapy Informed Consent
SCID Event Should Be Included In All Retroviral Therapy Informed Consent
Advertisement
UsernamePublicRestriction

Register

PS041126

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel